As the cannabis sector continues to expand and grow other industries have taken notice and started dipping their toes on investment possibilities. Case in point, on Monday (October 30), Constellation Brands (NYSE:STZ), a giant in the alcohol production industry, announced an investment deal with one of the leading cannabis LPs in Canada, Canopy Growth (TSX:WEED).
According to the announcement, Constellation will receive 9.9 percent equity of Canopy for $245 million. Canopy also told investors it had issued 18,876,901 warrants to an affiliate of Constellation as part of the agreement.
Bruce Linton, Canopy’s CEO, said the company plans to learn from the team at Constellation on growing brands–a topic Linton spoke about at length during a presentation earlier this year.
In an interview with the Wall Street Journal, Constellation chief executive officer Rob Sands said the deal is a direct response to an expectation for cannabis to be legalized in the US.
Constellation emphasized it does not plan to sell any type of cannabis products until it is legal to do so. The company plans to close the transaction by their third quarter of their fiscal year 2018.
Since Monday’s announcement, Canopy stock has increased 26.11 percent. On Thursday (November 2), following a confirmation statement from Canopy on the deal, the company experienced a volume of 3.95 million, representing the number of shares traded that day.
Financial analyst weighs in the move by Constellation
In an interview with Business News Network Vivien Azer, an analyst at Cowen & Co., said she applauded Constellation for earning the status of the first mover as an alcohol company making a formal bet in cannabis.
Azer added she wouldn’t be surprised to see more deal similar to the Canopy one to begin between cannabis, alcohol companies, and tobacco ones.
When asked if the momentum from changes of regulation at a state level will elevate all the way to the federal level Azer said she doesn’t expect any changes “under the current administration.”
The state-level momentum should put the US in a position, with a change in administration for a broader shift in cannabis regulation,” Azer said.
A report by CNBC indicated Constellation would be working with Canopy to start developing “cannabis-infused beverages,” which could potentially open a whole new opportunity for the sector.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.